title: Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men.
abstract: Previous studies have suggested that serum prostate-specific antigen (PSA) levels are under androgenic influence, especially in patients with adenocarcinoma of the prostate. PSMA (prostate-specific membrane antigen) is thought to reflect hormonal or clonal resistance or an independence with respect to testosterone regulation. The influence of testosterone on serum PSA expression in normal men is not clear. We studied the effect of exogenous testosterone administration on the serum levels of PSA and PSMA in hypogonadal men. Serial serum PSA, serum PSMA by Western blot, and serum total testosterone levels were obtained at intervals of every 2-4 weeks in 10 hypogonadal men undergoing treatment with exogenous testosterone, delivered as testosterone enanthate injection or by testosterone patch. Linear and quadratic orthogonal polynomial scores were calculated for PSMA, PSA, and testosterone. A 2-tailed, paired t-test failed to demonstrate a significant correlation between serum PSA (linear P = 0.432, quadratic P = 0.290) or PSMA (linear P = 0.162, quadratic P = 0.973) and serum testosterone levels. This study suggests that in hypogonadal men, neither PSMA nor PSA expression is testosterone-dependent.
authors.affiliation: Department of Surgery, Walter Reed Army Medical Center, Washington, D.C. 20307-5001, USA.
authors.forename: T H
authors.initials: TH
authors.lastname: Douglas
authors.forename: R R
authors.initials: RR
authors.lastname: Connelly
authors.forename: D G
authors.initials: DG
authors.lastname: McLeod
authors.forename: S J
authors.initials: SJ
authors.lastname: Erickson
authors.forename: R
authors.initials: R
authors.lastname: Barren
authors.forename: G P
authors.initials: GP
authors.lastname: Murphy
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood*; D000954:Antigens, Surface / Q000097:blood*; D043425:Glutamate Carboxypeptidase II; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D013739:Testosterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use
chemical_list: D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D013739:Testosterone; C004648:testosterone enanthate; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II; D017430:Prostate-Specific Antigen